Craig-Hallum raised the firm’s price target on BioLife Solutions (BLFS) to $32 from $30 and keeps a Buy rating on the shares. The firm notes BioLife delivered a strong Q3 update that featured a fourth consecutive quarter of revenue growth and continued margin improvement. Earlier in the day the company had announced the divestiture of their SciSafe business unit for $73M as the company refocuses on high-margin cell processing products.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLFS:
- BioLife Solutions price target raised to $31 from $28 at TD Cowen
- BioLife Solutions Reports Strong Q3 2024 Results
- BioLife Solutions lowers FY24 revenue view to $98.0M-$100.0M from $99.0M-$101.0M
- BioLife Solutions reports Q3 ContOps GAAP EPS (4c), consensus (9c)
- BLFS Earnings this Week: How Will it Perform?